Real world experience in the era of first generation protease inhibitors in the treatment of hepatitis C

Research output: Contribution to journalArticlepeer-review

Abstract

The treatment for hepatitis C has been revolutionized with the new era of protease inhibitors. Boceprevir (BOC) and telaprevir (TVR) are potent first generation direct acting antivirals which have demonstrated significantly improved response rates compared to interferon and ribavirin in phase III trials. However there are multiple real-life data sets showing increased adverse events and treatment discontinuations compared to clinical trials, especially in the cirrhotic patient. The advent of all oral, non-interferon regimens offers a promising treatment paradigm for hepatitis C infected patients.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalCurrent Hepatitis Reports
Volume12
Issue number4
DOIs
StatePublished - Dec 2013

Keywords

  • Acting
  • Antivirals
  • Boceprevir
  • Direct
  • Experience
  • Hepatitis c
  • Inhibitors
  • Protease
  • Real
  • Telaprevir
  • Treatment
  • World

ASJC Scopus subject areas

  • Hepatology
  • Virology

Fingerprint Dive into the research topics of 'Real world experience in the era of first generation protease inhibitors in the treatment of hepatitis C'. Together they form a unique fingerprint.

Cite this